Compare Aurobindo Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC LTD - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC LTD AUROBINDO PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 8.7 46.2 18.8% View Chart
P/BV x 1.6 1.9 85.0% View Chart
Dividend Yield % 0.7 0.5 121.4%  

Financials

 AUROBINDO PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ALEMBIC LTD
Mar-18
AUROBINDO PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs83072 1,152.8%   
Low Rs52734 1,554.9%   
Sales per share (Unadj.) Rs333.94.7 7,103.4%  
Earnings per share (Unadj.) Rs40.46.1 661.2%  
Cash flow per share (Unadj.) Rs51.86.2 828.7%  
Dividends per share (Unadj.) Rs2.500.20 1,250.0%  
Dividend yield (eoy) %0.40.4 97.5%  
Book value per share (Unadj.) Rs237.140.7 583.1%  
Shares outstanding (eoy) m585.91267.03 219.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.011.3 18.0%   
Avg P/E ratio x16.88.7 193.8%  
P/CF ratio (eoy) x13.18.5 154.6%  
Price / Book Value ratio x2.91.3 219.8%  
Dividend payout %6.23.3 189.1%   
Avg Mkt Cap Rs m397,56914,139 2,811.8%   
No. of employees `00017.9NA-   
Total wages/salary Rs m25,849207 12,463.2%   
Avg. sales/employee Rs Th10,956.9NM-  
Avg. wages/employee Rs Th1,447.7NM-  
Avg. net profit/employee Rs Th1,324.3NM-  
INCOME DATA
Net Sales Rs m195,6361,255 15,586.0%  
Other income Rs m1,553370 419.6%   
Total revenues Rs m197,1891,625 12,131.7%   
Gross profit Rs m39,519111 35,571.0%  
Depreciation Rs m6,68038 17,670.6%   
Interest Rs m2,6262 154,470.6%   
Profit before tax Rs m31,767442 7,190.4%   
Minority Interest Rs m270-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,26924 30,348.6%   
Profit after tax Rs m23,6451,630 1,450.7%  
Gross profit margin %20.28.9 228.2%  
Effective tax rate %22.95.4 422.1%   
Net profit margin %12.1129.8 9.3%  
BALANCE SHEET DATA
Current assets Rs m153,6451,867 8,229.1%   
Current liabilities Rs m120,429591 20,370.3%   
Net working cap to sales %17.0101.6 16.7%  
Current ratio x1.33.2 40.4%  
Inventory Days Days13594 143.4%  
Debtors Days Days6474 86.6%  
Net fixed assets Rs m103,9091,791 5,802.0%   
Share capital Rs m586534 109.7%   
"Free" reserves Rs m138,32210,324 1,339.9%   
Net worth Rs m138,90810,858 1,279.3%   
Long term debt Rs m1,80041 4,367.7%   
Total assets Rs m264,54411,591 2,282.4%  
Interest coverage x13.1260.9 5.0%   
Debt to equity ratio x00 341.4%  
Sales to assets ratio x0.70.1 682.9%   
Return on assets %9.914.1 70.5%  
Return on equity %17.015.0 113.4%  
Return on capital %23.815.2 156.9%  
Exports to sales %49.61.5 3,211.0%   
Imports to sales %18.821.0 89.5%   
Exports (fob) Rs m97,09119 500,470.1%   
Imports (cif) Rs m36,741263 13,952.0%   
Fx inflow Rs m97,31619 501,630.9%   
Fx outflow Rs m40,589264 15,385.2%   
Net fx Rs m56,727-244 -23,208.9%   
CASH FLOW
From Operations Rs m16,220236 6,878.8%  
From Investments Rs m-28,768-224 12,843.0%  
From Financial Activity Rs m19,191-27 -72,145.1%  
Net Cashflow Rs m6,656-15 -44,975.7%  

Share Holding

Indian Promoters % 54.1 64.0 84.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.2 3,975.0%  
FIIs % 27.7 9.7 285.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 26.1 39.1%  
Shareholders   69,601 54,701 127.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 3, 2020 03:35 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - BIOCON COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS